Accelerate Diagnostics (NASDAQ:AXDX) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Tuesday, BidAskClub reports.

Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, April 19th. ValuEngine raised shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, May 10th. Finally, BTIG Research reissued a “hold” rating on shares of Accelerate Diagnostics in a research report on Sunday, May 12th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $19.67.

Shares of AXDX stock opened at $20.12 on Tuesday. The company has a debt-to-equity ratio of 2.86, a current ratio of 25.36 and a quick ratio of 24.03. Accelerate Diagnostics has a one year low of $10.23 and a one year high of $24.75.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. The firm had revenue of $1.75 million during the quarter, compared to analysts’ expectations of $2.12 million. Accelerate Diagnostics had a negative net margin of 1,352.80% and a negative return on equity of 130.94%. Sell-side analysts anticipate that Accelerate Diagnostics will post -1.6 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC raised its position in shares of Accelerate Diagnostics by 25.1% in the fourth quarter. FMR LLC now owns 738,449 shares of the medical research company’s stock valued at $8,492,000 after purchasing an additional 148,099 shares during the period. Stifel Financial Corp increased its position in Accelerate Diagnostics by 24.6% during the fourth quarter. Stifel Financial Corp now owns 556,763 shares of the medical research company’s stock worth $6,365,000 after acquiring an additional 110,034 shares during the period. Raging Capital Management LLC bought a new position in Accelerate Diagnostics during the fourth quarter worth about $2,518,000. Metropolitan Life Insurance Co. NY increased its position in Accelerate Diagnostics by 331.4% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,727 shares of the medical research company’s stock worth $100,000 after acquiring an additional 6,704 shares during the period. Finally, Chicago Capital LLC increased its holdings in Accelerate Diagnostics by 16.4% in the 1st quarter. Chicago Capital LLC now owns 493,819 shares of the medical research company’s stock valued at $10,380,000 after buying an additional 69,629 shares during the period. 50.09% of the stock is currently owned by institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

See Also: How Important is Technical Analysis of Stocks

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.